In addition, either high MIFT-levels or a low MIFT/AXL-ratio were shown to be associated with resistance of BRAF-and NRAS-mutant melanoma cells towards kinase inhibitors and other targeted therapies [86]. The gene discussed is AXL; the disease is melanoma.